Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
64.9.276.2690
Address
Unit 107 23 Edwin Street Mount Eden, Auckland 1024
Description
Algorae Pharmaceuticals Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company was founded by Robert Bartlett Elliot and David Collinson in 1987 and is headquartered in Mount Eden, New Zealand.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.02
Trade Value (12mth)
AU$3,750.00
1 week
0%
1 month
0%
YTD
-20%
1 year
-42.86%
All time high
0.59
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
-$2m
Free Cash Flow Return
-45.00%
ROIC
-61.80%
Interest Coverage
N/A
Quick Ratio
17.90
Shares on Issue (Fully Dilluted)
1687m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
02 September 24 |
Notification of cessation of securities - 1AI
×
Notification of cessation of securities - 1AI |
30 August 24 |
Annual Report and Appendix 4E
×
Annual Report and Appendix 4E |
30 August 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
31 July 24 |
Positive results from AI-116 in vitro studies
×
Positive results from AI-116 in vitro studies |
22 July 24 |
Quarterly Activities Report /Appendix 4C Cash Flow Statement
×
Quarterly Activities Report /Appendix 4C Cash Flow Statement |
01 July 24 |
Change of Company Secretary
×
Change of Company Secretary |
16 May 24 |
Application for quotation of securities - 1AI
×
Application for quotation of securities - 1AI |
16 May 24 |
Cleansing Notice
×
Cleansing Notice |
09 May 24 |
Change of Company Secretary
×
Change of Company Secretary |
30 April 24 |
Application for quotation of securities - 1AI
×
Application for quotation of securities - 1AI |
30 April 24 |
Cleansing Notice
×
Cleansing Notice |
29 April 24 |
Quarterly Activities Report /Appendix 4C Cash Flow Statement
×
Quarterly Activities Report /Appendix 4C Cash Flow Statement |
26 April 24 |
Application for quotation of securities - 1AI
×
Application for quotation of securities - 1AI |
23 April 24 |
Proposed issue of securities - 1AI
×
Proposed issue of securities - 1AI |
22 April 24 |
Notification of cessation of securities - 1AI
×
Notification of cessation of securities - 1AI |
22 April 24 |
Application for quotation of securities - 1AI
×
Application for quotation of securities - 1AI |
18 April 24 |
1AI Corporate Presentation
×
1AI Corporate Presentation |
08 April 24 |
Positive results from AI-116 in vitro studies
×
Positive results from AI-116 in vitro studies |
26 March 24 |
Results of Meeting
×
Results of Meeting |
20 March 24 |
Upcoming Expiry Of 1AIOA Quoted Option Series
×
Upcoming Expiry Of 1AIOA Quoted Option Series |
08 March 24 |
Artificial Intelligence Platform Update
×
Artificial Intelligence Platform Update |
08 March 24 |
Application for quotation of securities - 1AI
×
Application for quotation of securities - 1AI |
08 March 24 |
Cleansing Notice
×
Cleansing Notice |
29 February 24 |
Half Yearly Report Announcement and Appendix 4D
×
Half Yearly Report Announcement and Appendix 4D |
29 February 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.